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treatment and monthly up until 3 months after finishing treatment. 
Treatment outcome at 3 and 6 months was retrieved in 131 patients. 
A two-tailed Fisher’s Exact test was used to compare binary data 
between both arms. A Mann-Whitney U test was performed to 
compare continuous data.  
Results: Data of 193 patients could be retrieved (experimental arm: 
n=96 , standard arm: n= 97). No significant differences between both 
arms were seen in social status, age, sex, tumor site, smoking and 
alcohol abuse, TNM stage, performance stage, total dose delivered, 
overall treatment time and pretreatment dysphagia. Dosimetrically, 
no significant difference was seen between both arms concerning 
PTVther coverage (for D95: 67.5 Gy vs 67.3 Gy; p=0.9). As expected the 
median D95 of the PTVelect was significantly lower in the experimental 
arm than in the standard arm (39.5 Gy vs 49.8 Gy; p<0.0001). Using 
this strategy we were able to significantly reduce the dose to 
swallowing structures (Table 1). There was no significant difference in 
acute mucositis, skin toxicity and weight loss between both groups. 
During treatment no difference was seen in severe dysphagia. Three 
months after radiotherapy however there was significantly less grade 
3+ dysphagia in the experimental arm compared to the standard arm 
(2% vs 11%; p=0.03) (Figure 1). At 6 months, no significant difference 
was seen in locoregional control between both arms (88% vs 92%; 
p=0.6). 
Conclusions: Using IMRT we were able to significantly reduce the dose 
to the elective nodal volumes and several organs at risk without 
compromising PTVther coverage. This resulted in a significant reduction 
of severe dysphagia 3 months after radiotherapy, without 
compromising locoregional control. Further follow-up is necessary to 
investigate whether these observations translate into a benefit on late 
treatment related dysphagia without affecting treatment outcome.  
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Purpose/Objective: To compare conventional fractionation 
radiotherapy (RT, Arm A), conventional fractionation RT with 
concurrent chemotherapy (CTRT, Arm B) and accelerated 
radiotherapy (ART, Arm C), in terms of survival and toxicity for loco-
regionally advanced, non-nasopharyngeal, Squamous Cell Carcinoma 
Head and Neck (HNSCC). 
Materials and Methods: Between April 2000 and October 2007, 179 
previously untreated, non metastatic, Stage III and IV HNSCC were 
randomised. There were 53, 64 and 62 patients in Arm A, B and C 
respectively. In arms A and B, all patients received conventional 
fractionation RT to a total dose of 66-70Gy in 6-7 weeks, five fractions 
per week. In Arm B, concurrent CT regimen consisted of Cisplatin 30 
mg/m2/week. In Arm C, the total dose of radiotherapy was same, 6 
fractions were administered per week, with concomitant boost being 
given on Saturday. Analysis was on an intention-to-treat basis. 
Results: The median age of cohort was 49 years. The age, sex, 
primary sites, stage of disease were equally distributed in all three 
arms. Oropharynx was the most common primary site in all the three 
arms. The median treatment duration was 49, 51 and 40 days in 3 
arms respectively. In arm B, the median number of chemotherapy 
cycles was 6. The mean and median follow up was 37.7 and 23 months 
respectively (Inter-quartile range 10-59 months). There was a 
significant difference in the Disease-Free Survival (DFS) and Overall 
survival (OS) for CT-RT arm compared with the others. The Median 
DFS in Arm A was 16 months compared to 34 months in Arm B and 10 
months in Arm C (p=0.02). Median OS in Arm A was 32 months 
compared to 76 months in Arm B and 32 months in Arm C (p=0.05). In 
terms of acute toxicities patients of Arm A experienced fewer Grade 3 
or more oral mucositis compared to Arms B & C (11 versus 22 versus 
19 respectively). No incidence of G3 or more haematological toxicity 
was seen during the treatment in either of the arms. There was no 
difference in acute grade 3 skin toxicity or significant sequelae 
between the arms (14 versus 15 versus 10 respectively). In terms of 
late toxicities (RTOG Scale) G2-G3 xerostomia was similar in all the 
three arms (10 versus 14 versus 11 respectively). Similarly the late 
toxicity in terms of skin, mucosa and subcutaneous tissue was similar 
in the 3 arms. Salvage surgery was done in 19 patients (4 versus 6 
versus 9 respectively in Arms A, B & C). Thirteen patients developed 
second primary cancer (3 versus 5 versus 5 respectively in Arms A, B & 
C). 
Conclusions: Concurrent CTRT is associated with significant better OS 
and DFS as compared to RT alone (Conventional or Accelerated) 
without significant increase in late toxicities.  
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Purpose/Objective: To assess the role of domiciliary based 
humidification (HUM) on the natural history of mucositis during 
radiotherapy (RT) for head and neck cancer. To evaluate the impact 
of HUM on patient reported outcomes (PRO). 
Materials and Methods: In this phase III multi-site trial, patients with 
SCC of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx 
receiving definitive or adjuvant RT ± chemotherapy were randomised 
to either institutional standard of care (control) or HUM using the 
Fisher and Paykel Healthcare MR880 humidifier. HUM commenced day 
1 of RT and continued until CTCAE version 3.0 mucositis clinical exam 
score (CMuc) was <1. Compliance was recorded electronically. HUM 
Compliance ratio (HCR) was calculated using the formula: total days 
compliance > 4 hours from RT start to CMuc < grade 1 / total days 
from RT start to CMuc <grade 1. HCR of > 0.33 was set as the cutoff 
for the per protocol population analysis (PPA). CMuc was assessed 
weekly until week 12 or resolution of CMuc score < 1. The primary 
endpoint was the area under the curve (AUC) of CMuc grade >1. A 
credentialing programme promoted CMuc scoring consistency among 
investigators. The secondary endpoint CTCAE v 3.0 mucositis 
functional score (FSMuc) was analysed with similar methodology. PRO 
assessments included McMaster University Head and Neck 
Questionnaire (HRNQ) at baseline, 4, 7,12 and 20 weeks. Symptom 
cluster questions within HRNQ associated with mucositis analysed in 
addition to the normal HNRQ domains included severe cluster 
(difficulty tasting food, clearing secretions, swallowing or chewing) 
and moderate cluster (low energy, fatigue, dryness mouth, reduced 
appetite, pain mouth, pain throat, difficulty sleeping). The primary 
PRO comparison was the difference in means between the 2 arms at 
each timepoint. 
Results: 210 patients were randomised (control 105; HUM 105). There 
was no difference in AUC CMuc means for the intention to treat 
population (ITT): control 9.0 (95% CI; 8.1 – 10.0); HUM 8.9 (95% CI; 8.0 
–9.8); p 0.97. When patients with HCR < 0.33 were excluded for the 
PPA (60HUM patients; 58%), there was again no difference: control 9.0 
(8.1 – 10.0) HUM 7.8 (6.3 – 9.2) p 0.25. There was no difference in AUC 
FSMuc for ITT: control 9.6 (8.7 – 10.4) HUM 8.8 (8.0 – 9.5); p 0.22, but 
a significant difference for PPA: control 9.6 (8.7 – 10.4) HUM 7.7 (6.7 – 
8.7); p 0.009. For HNRQ ITT analysis, there was no difference in 
outcomes at any timepoint. The HNRQ PPA showed few significant 
differences but estimates were in the direction that favoured HUM 
with less symptom severity. 
Conclusions: There was no difference in the primary endpoint of AUC 
CMuc with HUM. There is a trend in the HNRQ PPA suggestive of 
efficacy with HUM which is reflected in the AUC FSMuc PPA as well but 
the major difficulties in achieving consistent patient compliance 
suggests this is not an effective therapy for mucositis in its current 
format.  
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Treatment of patients with oligo-metastasic disease has moved into 
focus since it has been shown that limited disease volume and sites 
contribute favorably to outcome. This is also relevant in metastastic 
lesions to the brain. However, due to the dose-response relationship 
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known for the treatment of brain metastases and due to the sensitive 
organ at risk, i.e. the brain and its eloquent regions, dose and volume 
have to be selected cauteously when treating such patients. 
With highly precise techniques such as radiosurgery or 
hypofractionated treatments, the dose required is dependent on 
several factors, including volume of the lesion, vicinity to normal 
tissue structures, pre-existing clinical symptoms, overall performance 
status of the patient including prognosis, as well as underlying 
disease. All factors must be taken into account in clinical decision 
making, reflecting dose and volume recommendations from published 
clinical studies. The main limiting factor is the development of 
unwanted effects after treatment, also including neurocognitive 
functioning and preservation of quality of life (QOL).  
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The use of whole-brain radiotherapy remains a topic of great 
controversy. Historically, whole-brain radiotherapy has been the 
standard treatment for all patients with brain metastases. 
Randomized trials confirmed that in selected patients with limited, 
especially solitary brain metasteses, the addition of local treatment 
(surgery, radiosurgery) improves overall survival.  
Conversely, other trials have asked whether in such patients with 
limited brain metastases, "upfront" whole-brain radiotherapy is 
necessary or can be delayed after local therapy only. The randomized 
EORTC trial 22952-26001 confirmed that adding whole-brain 
radiotherapy to local treatment of brain metastases improves local 
control, distant brain control but not overall survival [Kocher et al., J 
Clin Oncol 2011].  
Whole-brain radiotherapy does have adverse effects on neurocognitive 
function and quality of life as has been demonstrated by meticulous 
studies of its prophylactic use in small-cell lung cancer [Le Pechoux et 
al., Ann Oncol 2011]. Assuming that intracranial tumor control is a 
prerequisite for maintaining neurocognitive function and performance 
status, the benefit of whole-brain radiotherapy in individual patients 
will depend on the "net effect" (beneficial regression of metastases vs. 
toxicity). The most recent quality-of-life analysis of the above EORTC 
trial indicates that patients in the arm with whole-brain radiotherapy 
had worse scores in some areas than patients in whom this treatment 
was initially withheld [Soffietti et al., J Clin Oncol 2013]. 
In patients with oligometastatic brain disease who are not candidates 
for local treatment, whole-brain radiotherapy may also have 
limitations. Recent data from a large prospective quality-of-life study 
show that many functions and symptoms deteriorate within three 
months after radiotherapy [Steinmann et al., BMC Cancer 2012].  It is 
under discussion if patients in poor performance status (RPA class 3) 
should receive whole-brain radiotherapy or best supportive care 
alone.  
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The majority of patients with brain metastases (BM) from solid tumors 
have a prognosis of only a few months, based on unfavorable factors 
such as extensive extracranial tumor activity, and will be candidate 
for a short course of palliative whole brain radiotherapy (WBRT). 
Classification systems using independent prognostic factors such as 
performance status, primary tumor control, activity of extracranial 
metastases and age enable identifying subsets of patients that may 
have long-term survival, provided that the BM can be treated 
aggressively. For the these selected groups of patients with 
‘oligometastatic’ disease, several more aggressive techniques for 
treatment of BM are available, including neurosurgery, radiosurgery or 
a combination of WBRT and radiosurgery.  
Radiosurgery, a well-established treatment modality for a limited 
number of BM, involves the high-precision delivery of usually a single 
fraction of approximately 18-20 Gy directed to the lesion(s), resulting 
in local control rates of 60-90%, dependent on the size and aspect of 
the lesion (poorer control for necrotic lesions). Although radiosurgery 
has been available in the clinic for decades, recent years have seen 
major advances in treatment planning and delivery. In particular, the 
introduction of ‘frameless’ radiosurgery techniques with dedicated 
mask systems replacing invasive frames, has greatly facilitated 
logistics and lowered the threshold for accepting patients for 
radiosurgery. Several radiation delivery techniques are available 
ranging from multiple fixed beams, multiple non-coplanar arcs using 
cones or high-definition multileaf collimation, and recently also 
intensity modulated arcs or Tomotherapy.    
The question whether WBRT should be added to RS has been a long-
standing unresolved issue with proponents highlighting the improved 
intracranial control, and opponents pointing out the neurocognitive 
toxicity of WBRT and available salvage options.The recently 
completed EORTC study 22952-26001 has not been able to resolve the 
controversy, as it again showed that adjuvant WBRT after radiosurgery 
(or surgery) in a limited number of BM reduces intracranial relapses 
and neurologic deaths, but failed to improve the duration of 
functional independence and overall survival. As the risk of developing 
new BM following RS alone is not only dependent on extracranial 
tumor activity (reseeding) but also on the number of initially treated 
BM, a more differentiated approach towards adjuvant WBRT may be 
better suited, with for instance radiosurgery used as a single modality 
for 1 or 2 brain lesions, and a combination of WBRT and radiosurgery 
for multiple lesions. 
A well selected patient group with multiple BM in good performance 
status and absent progressive extracranial disease may be candidates 
for radiation delivery integrating WBRT and stereotactic (fractionated) 
radiosurgery. Techniques such as volumetric intensity-modulated arc 
therapy (VMAT, RapidArc) or Tomotherapy have enabled fast and 
accurate delivery of fractionated stereotactic integrated boosts to 
multiple BM in combination with WBRT. The integrated approach of 
this planning technique allows steep dose gradients to be generated 
outside the boosts to the BM, much steeper than with a conventional 
summation of WBRT and radiosurgery (Figure; conventional left panel, 
VMAT right panel). This could theoretically decrease toxicity that has 
been observed in previous combined modality studies. Another 
advantage of this volumetric arc approach is that even complex 
treatment plans can be delivered within just minutes, although the 
use of a single isocentre instead of multiple isocentres necessitates 
dedicated patient setup including correction of rotational errors. Early 
experience with this technique have reported relatively high 
intracranial control, but it remains important to identify appropriate 
‘oligometastatic’ patients in order to justify this advanced treatment 
delivery. At the time of the meeting, some planning considerations 
and preliminary clinical results will be presented. 
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Purpose/Objective: Diffusion weighted MRI (DWI) is increasingly being 
used in head and neck cancer, where response prediction might 
become an important application for treatment personalization. DWI 
and the derived apparent diffusion coefficient (ADC) reflect 
microstructural features of tissues, as water diffusion can be 
restricted by cell membranes and tortuosity in the extracellular 
matrix. In head and neck squamous cell carcinomas (HNSCC), a 
correlation has been found between local failure after 
(chemo)radiotherapy and pre-treatment apparent diffusion coefficient 
(ADC) [1]. However, the pathohistological basis of this correlation is 
not clear. The aim of this study was to investigate how histological 
characteristics of HNSCC are related to ADC. 
Materials and Methods: Sixteen patients with laryngeal or 
hypopharyngeal squamous cell carcinomas were enrolled (median age 
60 years, range 49-78 years). Before having a total laryngectomy 
(TLE), patients underwent 1.5 Tesla MRI including diffusion weighted 
single shot spin echo echo planar imaging (DWI) with STIR fat 
suppression, TR/TE 5872/70ms, TI 180ms, nsa 4, FOV25x20cm2, slice 
thickness 4mm, matrix 121x101mm2. ADC maps were created with a 
linear fit of the signal intensity of the DWI with b 150 and 800 s/m2. 
After resection, whole-mount heamatoxylin-eosin–stained sections 
